Overall rank by patents
#24,987
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 3 technology areas, active 2015–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
The verdict
Parenteral holds 11 US patents across 3 technology areas, rank #24,987 of 50,000 tracked assignees.
Parenteral Technologies, Llc has been granted 11 US utility patents between 2015 and 2022, placing Parenteral Technologies, Llc at rank #24,987 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.4 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, Parenteral Technologies, Llc is one of the more focused assignees in the PatentsView dataset. By volume, Parenteral sits between Packaging Technologies & Inspection, Llc (11 patents, rank #24,983) and Peptidream Inc. (11 patents, rank #24,991) - the closest US assignees by grant volume. The composite Innovation Score of 29.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 5 grants, compared with 6 in the 2015–2019 window, a -17% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Parenteral Technologies, Llc's 16.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Parenteral Technologies, Llc against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Packaging Technologies & Inspection, LLC
11 patents
Pandion Operations, Inc.
11 patents
Paper-Pak Industries
11 patents
Paradigm Health and Wellness
11 patents
Parker Hannifin Manufacturing Limited
11 patents
Pattern Bioscience, Inc.
11 patents
PendoTECH
11 patents
PeptiDream Inc.
11 patents
Parenteral Technologies, LLC
11 patents
What this shows Parenteral holds 11 patents at rank #24,987, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Parenteral's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
29 Top 71% higher than 29% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 9.1% |
| 2016 | 2 | 18.2% |
| 2017 | 2 | 18.2% |
| 2018 | 1 | 9.1% |
| 2020 | 2 | 18.2% |
| 2021 | 1 | 9.1% |
| 2022 | 2 | 18.2% |
Top 3 of 3 technology areas
Overall rank by patents
#24,987
Across all tracked assignees
29.0 out of 100
How to use this portfolio
Parenteral's 11 grants land it in the top 71% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.